Study Group: Lipitor Prescribers for Angina(?)
Council Members in this Study Group: 16
Request a survey with this Study Group
Leading Experts in this Study Group
Clinical Director
New York University Medical Center
Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...
Harold Bays, MD, FACPPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...
Cardiologist
New York University Medical Center
Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology. He has lectured frequently on such topics as...
Charles Glueck, MDMedical Research Director of Cholesterol Center
Jewish Hospital
Charles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology, and hematology. Dr Glueck and colleagues...
Hossein Ghofrani, MDPhysician
Justus Liebig Universitat Giessen
Hossein Ardeschir (Ardi) Ghofrani, MD, is Lead physician of the Pulmonary Hypertension Centre at the University of Giessen Lung Center (UGLC), Germany. Prof. Ghofrani is a Reviewer for various high impact scientific journals including Lancet, AJRCCM, Circulation, and Circulation research amongst others....
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Given the economic pressures on patients, they are now more likely to ask for generic medications than they were in the past. Given that there are generic versions of several classes of medications, physicians such as me are more likely to comply with a patient's request for a generic than in...
I am a heavy user of ARB's and Tekturna. This article does not really show anything of significance. Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
ExForge is a product that we in the hypertension business are very anxious to have available. Combination tablets have been increasing in sales very dramatically in the past few years and will soon overtake, in my opinion, single agents. Lotrel led the way toward combinations that do not include a diuretic...
GLG InstituteSM Seminars with this Study Group's Leading Experts(?)
Recent Seminars
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Contract Research Organization, Independent/Small
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Director
- President
- Chief Executive Officer
- Medical Director
- Partner
- Owner